A new drug combo for hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of four drugs (venetoclax, homoharringtonine, azacitidine, and G-CSF) for people with newly diagnosed AML who cannot tolerate standard intensive chemotherapy. The goal is to see if this lower-intensity therapy can effectively treat the leukemia with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute myeloid leukemia (AML).
- You should not have had any previous chemotherapy or similar drugs for AML.
- You need to be 75 years or older, or between 18 and 74 with certain health problems (like heart or lung issues) that make standard chemo too risky.
- Your kidney function must be at least moderate (creatinine clearance ≥ 30 mL/min), and your liver function must be within safe limits.
- You cannot have certain other cancers or infections (like active tuberculosis) that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (lisafotoclax, decitabine, and homoharringtonine) for people with AML who have already tried venetoclax and azacitidine and it didn’t work. The goal is to find a treatment that might work when the first therapy fails.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.